Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORANE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Induction and maintenance of general anesthesia,Sedation for mechanical ventilation in intensive care
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Context-sensitive half-life: 2-5 minutes after short exposure; prolonged to 30-60 minutes after prolonged administration due to accumulation in fat and muscle. Terminal elimination half-life: 0.5-1 hour.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via CYP2E1; also undergoes glucuronidation and defluorination.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily exhaled unchanged via lungs (>95%); <5% metabolized in liver to fluoride ions and other metabolites, which are excreted renally.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~40% bound to plasma proteins (mainly albumin).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd: 1.5-2.0 L/kg, reflecting distribution to highly perfused tissues (brain, heart, liver, kidneys) and subsequent redistribution to muscle and fat.
4-6 L/kg; large Vd indicates extensive tissue distribution
100% via inhalation.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No adjustment required.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Use with caution; reduce dose in severe hepatic impairment (Child-Pugh C).
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Induction: 1-4% inspired; Maintenance: 0.5-2% inspired.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Reduce inspired concentrations by 25-50% due to increased sensitivity.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of malignant hyperthermia,Respiratory depression,Hypotension,Hepatotoxicity with repeated use or in susceptible patients,Nephrotoxicity due to fluoride ions
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Known hypersensitivity to isoflurane or other halogenated agents,Known or suspected genetic susceptibility to malignant hyperthermia
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions are documented for isoflurane. However, patients should follow standard preoperative fasting guidelines (e.g., NPO for 8 hours prior to elective surgery) to reduce aspiration risk during anesthesia.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters: known to cause dose-dependent maternal hypotension and uterine relaxation, which may reduce placental perfusion; use only if clearly needed.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Isoflurane is excreted into breast milk in minimal amounts; M/P ratio is approximately 0.85. After inhalational anesthesia, the concentration in milk is low and rapidly cleared. The American Academy of Pediatrics considers it compatible with breastfeeding. However, it is recommended to discard milk for 24 hours post-procedure due to sedation and potential metabolites.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustment is required for pregnancy, but due to increased volume of distribution and decreased protein binding, a slightly lower dose may achieve desired anesthetic depth. Maintenance of uterine perfusion pressure is critical; avoid hypotension. The minimum alveolar concentration (MAC) is decreased by approximately 25% in pregnancy.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
FORANE (isoflurane) is a potent inhalational anesthetic with rapid onset and offset due to low blood-gas solubility. It causes dose-dependent respiratory depression and hypotension via peripheral vasodilation. Monitor end-tidal CO2 and arterial blood pressure closely. Avoid in patients with known or suspected malignant hyperthermia susceptibility. Use a calibrated vaporizer to deliver precise concentrations (1-3% for induction, 0.5-2% for maintenance).
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
This medication is for hospital use only and will be administered by an anesthesia provider.,You may experience drowsiness, dizziness, or confusion after waking from anesthesia.,Do not drive or operate machinery for at least 24 hours after receiving this drug.,Inform your doctor if you have a personal or family history of malignant hyperthermia.,Report any muscle rigidity, fever, or dark urine to your healthcare provider immediately.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORANE vs ABSTRAL, answered by our medical review team.
FORANE is a Inhalational Anesthetic that works by Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORANE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORANE is: Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORANE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORANE is classified as Category C. FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.